Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | XDH | P47989 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | GFER | P55789 | 1/20 | 0.65 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.65 |
| ▸ | RELA | Q04206 | 1/20 | 0.65 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | CA1 | P00915 | 4/20 | 0.61 |
| ▸ | CA2 | P00918 | 4/20 | 0.61 |
| ▸ | CA12 | O43570 | 3/20 | 0.61 |
| ▸ | CA7 | P43166 | 3/20 | 0.61 |
| ▸ | CA9 | Q16790 | 3/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.61 |
| ▸ | ESR1 | P03372 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21854475 | 0.92 | KDM4E (0.57) | KDM4ETDP1LMNAXDHPOLB | |
| SCHEMBL3356220 | 0.89 | KDM4E (0.53) | KDM4ETDP1LMNAXDHPOLB | |
| SCHEMBL401621 | 0.89 | LMNA (0.56) | KDM4ETDP1LMNAXDHPOLB | |
| SCHEMBL1312438 | 0.89 | KDM4E (0.58) | KDM4ETDP1LMNAXDHPOLB | |
| SCHEMBL10322876 | 0.89 | KDM4E (0.53) | KDM4ETDP1LMNAXDHPOLB | |
| SCHEMBL1406483 | 0.86 | GAA (0.50) | KDM4ETDP1LMNAXDHPOLB | |
| SCHEMBL31056132 | 0.86 | ERN1 (0.53) | KDM4ETDP1LMNAXDHPOLB | |
| SCHEMBL10322828 | 0.84 | KDM4E (0.49) | KDM4ETDP1LMNAXDHPOLB | |
| SCHEMBL20876266 | 0.84 | KDM4E (0.49) | KDM4ETDP1LMNAXDHPOLB | |
| SCHEMBL10321849 | 0.84 | NOTUM (0.50) | KDM4ETDP1LMNAXDHPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115850220-A | Stable amiodarone hydrochloride, preparation method and application thereof | 山东北大高科华泰制药有限公司 | 2023-03-28 | — | — | CN | claimed |
| CN-109988132-B | Preparation method of amiodarone hydrochloride | 浙江恒康药业股份有限公司 | 2020-12-01 | — | — | CN | claimed |
| US-20260092045-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2026-04-02 | — | — | US | disclosed |
| US-12558341-B2 | Oral complement factor D inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260035341-A1 | FTO INHIBITORS | RPXDS CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
| US-20250275991-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-09-04 | — | — | US | disclosed |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-06-12 | — | — | US | disclosed |
| EP-4561975-A1 | FTO INHIBITORS | RPXDS Co., Ltd (CN) | 2025-06-04 | — | — | EP | disclosed |
| EP-4524133-A2 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-115844817-B | Amiodarone hydrochloride injection and preparation method thereof | 山东北大高科华泰制药有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-119546566-A | FTO inhibitors | 瑞璞鑫(苏州)生物科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20040097743-A1 | Novel enantiomeric compounds for treatment of cardiac arrhythmias and methods of use | HESP LLC | 2004-05-20 | — | — | US | disclosed |
| US-6683195-B2 | 4-(2-DIETHYLAMINOETHOXY)-3,5-DIHALOBENZOYL DERIVATIVE AS ANTIARRHYTHMIA AGENT | ARYX THERAPEUTICS | 2004-01-27 | — | — | US | disclosed |
| US-20030083341-A1 | 2,3,5-Substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia | WYETH | 2003-05-01 | — | — | US | disclosed |
| US-20020193428-A1 | Novel enantiomeric compounds for treatment of cardiac arrhythmias and methods of use | HESP LLC | 2002-12-19 | — | — | US | disclosed |
| US-6451827-B2 | MODULATING BLOOD GLUCOSE CONCENTRATION | WYETH | 2002-09-17 | — | — | US | disclosed |
| US-20010018525-A1 | 2, 3, 5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia | WYETH | 2001-08-30 | — | — | US | disclosed |
| US-6214877-B1 | ANTIDIABETIC AGENTS; MODULATOR OF GLUCOSE CONCENTRATION | WYETH | 2001-04-10 | — | — | US | disclosed |
| EP-1077929-A1 | 2,3,5-SUBSTITUTED BIPHENYLS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999061410-A1 | 2,3,5-SUBSTITUTED BIPHENYLS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083341-A1 | 2,3,5-Substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia | INSR, GPR119, IRS1 | KDM4E 3852/4885TDP1 4517/4885LMNA 3208/4885 |
| US-20040097743-A1 | Novel enantiomeric compounds for treatment of cardiac arrhythmias and methods of use | RYR2, KCNN2, KCNH2 | KDM4E 2565/4885TDP1 3269/4885LMNA 224/4885 |
| US-20020193428-A1 | Novel enantiomeric compounds for treatment of cardiac arrhythmias and methods of use | RYR2, KCNN2, KCNH2 | KDM4E 2565/4885TDP1 3269/4885LMNA 224/4885 |
| US-20260035341-A1 | FTO INHIBITORS | FTO, LDLR, GPR119 | KDM4E 374/4885TDP1 722/4885LMNA 1168/4885 |
| US-20250275991-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | KDM4E 4182/4885TDP1 3664/4885LMNA 1900/4885 |
| US-20010018525-A1 | 2, 3, 5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia | INSR, GPR119, IRS1 | KDM4E 3851/4885TDP1 4516/4885LMNA 3208/4885 |
| US-20260092045-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | TFPI, F3, BTK | KDM4E 1536/4885TDP1 2446/4885LMNA 3855/4885 |
| US-12558341-B2 | Oral complement factor D inhibitors | CFD, CFH, CFB | KDM4E 4172/4885TDP1 4644/4885LMNA 1698/4885 |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | KDM4E 4491/4885TDP1 3520/4885LMNA 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.